tbuckley/cabot-search huggingface dataset:
Zebrafish: Speeding Up the Cancer Drug Discovery Process
Authors: Patricia Letrado, Irene de Miguel, Iranzu Lamberto, Roberto Díez-Martínez, Julen Oyarzabal
Journal: Cancer Research (2018)

Zebrafish (Danio rerio) is an ideal in vivo model to study a wide variety of human cancer types. In this review, we provide a comprehensive overview of zebrafish in the cancer drug discovery process, from (i) approaches to induce malignant tumors, (ii) techniques to monitor cancer progression, and (iii) strategies for compound administration to (iv) a compilation of the 355 existing case studies showing the impact of zebrafish models on cancer drug discovery, which cover a broad scope of scenarios. Finally, based on the current state-of-the-art analysis, this review presents some highlights about future directions using zebrafish in cancer drug discovery and the potential of this model as a prognostic tool in prospective clinical studies. Cancer Res; 78(21); 6048-58. ©2018 AACR.
PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake
Authors: Hamideh Parhiz, Vladimir V. Shuvaev, Norbert Pardi, Makan Khoshnejad, Raisa Yu Kiseleva, Jacob S. Brenner, Thomas Uhler, Steven Tuyishime, Barbara L. Mui, Ying K. Tam, Thomas D. Madden, Michael J. Hope, Drew Weissman, Vladimir R. Muzykantov
Journal: Journal of Controlled Release (2018)
Assessment of Challenges Encountered by Dutch Oncologists When Patients Ask for Second Opinions
Authors: Marij A. Hillen, F. J. Sherida H. Woei-A-Jin, Ellen M. A. Smets, Pomme E. A. van Maarschalkerweerd, Hanneke W. M. van Laarhoven, Dirkje W. Sommeijer
Journal: JAMA Oncology (2018)

Assessment of Challenges Encountered by Dutch Oncologists When Patients Ask for Second OpinionsMany patients with cancer seek second opinions to reconfirm their diagnosis, acquire more information, or receive better treatment. 1The desirability of a high rate of second opinions has been much debated.Proponents stress potential health gains, improved acceptance of initial diagnosis, and reduced anxiety for patients. 2Critics emphasize the limited clinical value, 3 potential treatment delays, and financial and logistical burdens for the health care system. 4The triadic nature of second-opinion consultations, involving 2 physicians and 1 patient, can further complicate communication and induce emotional sensitivities.This study investigates the challenges cancer specialists encounter when confronted with second-opinion requests.
Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine
Authors: Sachin G. Thakkar, Zachary N. Warnken, Riyad F. Alzhrani, Solange A. Valdes, Abdulaziz M. Aldayel, Haiyue Xu, Robert O. Williams, Zhengrong Cui
Journal: Journal of Controlled Release (2018)
<i>Notes from the Field:</i> Contact Tracing Investigation after First Case of Andes Virus in the United States — Delaware, February 2018
Authors: Aaron Kofman, Paula Eggers, Anne Kjemtrup, Rebecca Hall, Shelley M. Brown, Maria Morales-Betoulle, James Graziano, Sara E. Zufan, Shannon L.M. Whitmer, Deborah L. Cannon, Cheng-Feng Chiang, Mary J. Choi, Pierre E. Rollin, Martin S. Cetron, Hayley D. Yaglom, Monique Duwell, David T. Kuhar, Melissa Kretschmer, Barbara Knust, John D. Klena, Francisco Alvarado-Ramy, Trevor Shoemaker, Jonathan S. Towner, Stuart T. Nichol
Journal: MMWR Morbidity and Mortality Weekly Report (2018)
GW29-e0939 Transcatheter treatment of acute renal vascular injuries after nefrobiopsy
Authors: Kirill Smirnov, Alexey Biryukov, Dmitrii Ovcharenko, Gennadiy Khubulava, Alexey Khubulava, Andrei Voronkov, Roman Ivanchenko
Journal: Journal of the American College of Cardiology (2018)
Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma
Authors: L. Tan, S.K. Sandhu, R. Lee, J. Li, J. Callahan, J. Raleigh, A. Hatzimihalis, P. Middlehurst, M. Henderson, M. Shackleton, A. Haydon, D. Gyorki, D. Oudit, R.J. Hicks, P. Lorigan, G.A. McArthur, R. Marais, S.Q. Wong, S.-J. Dawson
Journal: Annals of Oncology (2018)
The study of molecular and genetic markers of apoptosis and proliferation, their role in the treatment and prevention of osteogenic sarcoma
Authors: M.N. Tillyashaykhov, D.S. Polatova, M.-A. Gafur-Akhunov, K. Abdikarimov, U. Islamov, R. Davletov
Journal: Annals of Oncology (2018)
GW29-e0001 Cinnameldehyde Attenuated Endothelial Dysfunction through Nrf2 Activation as a TRPA1 Agonist
Authors: Jindong Wan, Jingyu Kan, Jixin Hou, Dan Wang, Jiaxin Liu, Jiaxin Liu, Peijian Wang
Journal: Journal of the American College of Cardiology (2018)
Abstract P326: Myocardial Ischemia and Mobilization of Circulating Progenitor Cells
Authors: Muhammad Hammadah, Ayman Samman Tahhan, Ibhar Almheid, Bryan Ross Kindya, Mazen Ghafeer, Naser Abdelhadi, Oleskiy Levantsevych, Ayman Alkhoder, Wesley O’Neal, Malik Obideen, Heval Mohamed Kelli, Samaah Sulivan, Kobina Wilmot, Ronnie Ramadan, Pratik Pimple, Pratik Sandesara, Paolo Raggi, Amit J Shah, jinhee Kim, Edmund K Waller, Ernest V Garcia, Brad Pearce, David Sheps, Arshed Quyyumi, Viola Vaccarino
Journal: Circulation (2017)

Background: Circulating progenitor cells (CPCs) are involved in vascular repair and regeneration. Low levels of CPCs in patients with CAD have been linked to adverse cardiovascular outcomes. The response of CPCs to transient myocardial ischemia in patients with CAD has not been studied before. We aimed to investigate the CPC response to exercise provoked myocardial ischemia (demand ischemia), and compare it to myocardial ischemia detected during pharmacological stress test (flow mismatch). Methods: 570 patients with stable CAD underwent 99mTc sestamibi myocardial perfusion imaging during exercise (69%), or pharmacological stress (31%). myocardial ischemia was defined as a new or worsening impairment in myocardial perfusion using a 17-segment model. CD34+ CPCs were enumerated by flow cytometry at rest and 30 min after stress testing. The change in CPC count was compared between patients with and without myocardial ischemia using mixed linear models. Results: Mean age was 63±9 years, 76% males, 36% with previous myocardial infarction. The incidence of myocardial ischemia was 31% and 41% during exercise and pharmacological stress test, respectively. No difference was observed in resting CPC between patients undergoing exercise vs pharmacological stress test, nor between patients with or without myocardial ischemia. However, patients who developed myocardial ischemia during exercise stress had a significant decrease in CPC with stress in comparison to those without myocardial ischemia (-12% vs 4%, respectively, p=0.006). Furthermore, the change in CPCs was inversely correlated with the magnitude of myocardial ischemia (R=-0.13, p=0.023), suggesting a greater CPC reduction with larger ischemic burden. These findings remained significant even after adjustment for age, gender, race, BMI, previous myocardial infarction, resting levels of CPCs and hematocrit change with stress. No difference was observed in CPC response to pharmacological stress test (change of -1% vs 3%, for patients with and without myocardial ischemia, respectively, p=0.96). Conclusion: Exercise stress-induced myocardial ischemia is associated with a decrease in CPC counts, likely due to increased homing of stem cells to the ischemic myocardium. Whether the extent of CPC uptake has prognostic implication, or whether the CPC response can be altered with intervention needs further investigation.
Physician Characteristics Associated With Ordering 4 Low-Value Screening Tests in Primary Care
Authors: Zachary Bouck, Jacob Ferguson, Noah M. Ivers, Eve A. Kerr, Kaveh G. Shojania, Min Kim, Peter Cram, Ciara Pendrith, Graham C. Mecredy, Richard H. Glazier, Joshua Tepper, Peter C. Austin, Danielle Martin, Wendy Levinson, R. Sacha Bhatia
Journal: JAMA Network Open (2018)

Efforts to reduce low-value tests and treatments in primary care are often ineffective. These efforts typically target physicians broadly, most of whom order low-value care infrequently.To measure physician-level use rates of 4 low-value screening tests in primary care to investigate the presence and characteristics of primary care physicians who frequently order low-value care.A retrospective cohort study was conducted using administrative health care claims collected between April 1, 2012, and March 31, 2016, in Ontario, Canada. This study measured use of 4 low-value screening tests-repeated dual-energy x-ray absorptiometry (DXA) scans, electrocardiograms (ECGs), Papanicolaou (Pap) tests, and chest radiographs (CXRs)-among low-risk outpatients rostered to a common cohort of primary care physicians.Physician sex, years since medical school graduation, and primary care model.This study measured the number of tests to which a given physician ranked in the top quintile by ordering rate. The resulting cross-test score (range, 0-4) reflects a physician's propensity to order low-value care across screening tests. Physicians were then dichotomized into infrequent or isolated frequent users (score, 0 or 1, respectively) or generalized frequent users for 2 or more tests (score, ≥2).The final sample consisted of 2394 primary care physicians (mean [SD] age, 51.3 [10.0] years; 50.2% female), who were predominantly Canadian medical school graduates (1701 [71.1%]), far removed from medical school graduation (median, 25.3 years; interquartile range, 17.3-32.3 years), and reimbursed via fee-for-service in a family health group (1130 [47.2%]). They ordered 302 509 low-value screening tests (74 167 DXA scans, 179 855 ECGs, 19 906 Pap tests, and 28 581 CXRs) after 3 428 557 ordering opportunities. Within the cohort, generalized frequent users represented 18.4% (441 of 2394) of physicians but ordered 39.2% (118 665 of 302 509) of all low-value screening tests. Physicians who were male (odds ratio, 1.29; 95% CI, 1.01-1.64), further removed from medical school graduation (odds ratio, 1.03; 95% CI, 1.02-1.04), or in an enhanced fee-for-service payment model (family health group) vs a capitated payment model (family health team) (odds ratio, 2.04; 95% CI, 1.42-2.94) had increased odds of being generalized frequent users.This study identified a group of primary care physicians who frequently ordered low-value screening tests. Tailoring future interventions to these generalized frequent users might be an effective approach to reducing low-value care.
Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis
Authors: O. Hamid, A. Ribas, A. Daud, M.O. Butler, M.S. Carlino, W.-J. Hwu, G.V. Long, K. Ancell, F.S. Hodi, N.I. Khushalani, C.U. Blank, C. Loquai, J. Lin, S.J. Diede, C. Robert
Journal: Annals of Oncology (2018)
Abstract 17521: Safety and Efficacy of Centhaquin as a Novel Resuscitative Agent for Hypovolemic Shock
Authors: Ashish O Goyal, Manish S Lavhale, Anil Gulati
Journal: Circulation (2015)

Centhaquin (PMZ-2010) is a cardiovascular active agent (0.01 to 0.05 mg/kg) which has been shown to have resuscitative effect in a (1) rat model of fixed pressure blood loss, (2) rabbit model of uncontrolled bleeding with trauma, and (3) pig model of massive blood loss. PMZ-2010 produced a decrease in heart rate and vascular resistance; however, it increased mean arterial pressure by increasing cardiac output. We embarked on studies to develop PMZ-2010 as a resuscitative agent for hypovolemic shock. Toxicological studies were carried out and intravenous injection of PMZ-2010 in mice, rats and rabbits showed LD50 &gt;100 mg/kg, 79.43 mg/kg and 9.55 mg/kg, respectively. The No Observed Adverse Effect Level (N.O.A.E.L.) of PMZ-2010 determined after repeated (28 days) intravenous injections of different doses in mice, rats and rabbits was found to be 1.0 mg/kg. A 14 day repeated dose toxicity study of PMZ-2010 (0.01, 0.10 and 1.0 mg/kg, iv) in canine model (beagle dog) was conducted and there were no clinical symptoms of toxicity in low and middle whereas in high dose (1.0 mg/kg) temporary sluggishness, shivering and salivation was observed, while biochemical profile was normal in all groups. We conducted a single center randomized, double-blind, placebo-controlled, single and multiple-ascending dose phase I study in healthy male subjects to evaluate the safety of PMZ-2010 (NCT02408731). The study population comprised 6 cohorts of 4 subjects each, which were randomized so that 3 subjects received the active drug and 1 subject received placebo. For single ascending dose cohorts, the initial dose of PMZ-2010 was 0.005 mg/kg, iv infusion. Based on the safety and tolerability of the administered dose, subsequent escalation of doses 0.01, 0.05 0.10 and 0.15 mg/kg was performed and maximum tolerated dose (MTD) was found to be 0.10 mg/kg. For multiple-ascending dose cohorts, the initial dose/day of PMZ-2010 was equal to maximum tolerated dose (MTD) 0.10 mg/kg (3 X 0.033 mg/kg/day) for 2 days. Subsequent escalation of dose was done up to 2 times MTD 0.20 mg/kg (3 X 0.067 mg/kg/day) for 2 days. It is concluded that MTD of PMZ-2010 in humans is 0.10 mg/kg and can be safely used for its resuscitative effect. (Mr. Tajuddin and Dr. D. Chilkoti are acknowledged for assisting in clinical studies).
Knee osteoarthritis and bisphosphonates: Could BCP crystals be the missing link?
Authors: Claire-Louise M Murphy, Geraldine McCarthy
Journal: Annals of the Rheumatic Diseases (2018)

I read with interest your article regarding the potential of bisphosphonates for osteoarthritis (OA).1 Since OA affects the entire joint, it is unsurprising that there has been great difficulty developing an effective targeted treatment. The lifetime risk of symptomatic knee OA has been estimated to be as high as 44.7%,2 and …
Abstract 18595: Therapeutic Angiogenesis for Critical Limb Ischemia by Implantation of Autologous Adipose-Derived Regenerative Cells: A Clinical Pilot Study
Authors: Kazuhisa Kondo, Ryo Hayashida, Rei Shibata, Toyoaki Murohara
Journal: Circulation (2016)

Introduction: Therapeutic Angiogenesis by Cell Transplantation using autologous bone marrow-derived mononuclear cells (TACT-BM) represents a novel strategy for critical limb ischemia (CLI). However...
Analysis of Diagnostic Test Ordering Habits Among Internal Medicine Residents
Authors: Joshua D. Geleris, George Shih, Lia Logio
Journal: JAMA Internal Medicine (2018)

tors could help level the playing field for hospitals serving disadvantaged patients.Moreover, policymakers could provide underresourced hospitals with access to quality-improvement assistance or introduce downside risk more slowly for these hospitals.Additionally, creating separate tracks for low-and highvolume hospitals, and hospitals with vastly different clinical capabilities and resources, might persuade lower-volume, less well-resourced, and safety-net hospitals to join future bundled payment programs. 7 Ultimately, if bundled payments are to truly achieve their promise as a broadly viable tool for improving the efficiency of care, then policymakers and health systems leaders must make it easier for a diverse set of acute care hospitals to participate in and excel under bundled payment programs.
HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA)
Authors: E. Van Cutsem, P.G. Corrie, M.P. Ducreux, D. Sigal, V. Sahai, D.-Y. Oh, A. Bullock, Y.-J. Bang, A.D. Baron, A. Hendifar, C.-P. Li, P. Philip, M. Reni, M. Zalupski, L. Zheng, C. Berman, D. Chondros, M.A. Tempero
Journal: Annals of Oncology (2018)
Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma
Authors: C. Mignard, A. Deschamps-Huvier, A.-B. Duval-Modeste, C. Dutriaux, A. Khammari, M.-F. Avril, L. Mortier, T. Lesimple, C. Gaudy-Marqueste, C. Lesage, L. Machet, F. Aubin, N. Meyer, N. Beneton Benhard, G. Jeudy, H. Montaudié, J.-P. Arnault, M.-T. Leccia, P. Joly, S.F.D. Oncology Research Group Of The French Society Of Dermatology
Journal: Annals of Oncology (2018)
GW29-e0560 Lonicerae Japonicae Flose ameliorated myocardial fibrosis and improved cardiac function of isoproterenol-treated mice
Authors: Huimin Zhang, Yinglu Ren, Jinying Liu, Congping Su, Qing Wang, Xuan Xie, Lei Tian, Wei Wang, Shuzhen Guo
Journal: Journal of the American College of Cardiology (2018)
Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERMIONE non-interventional prospective study
Authors: J.-P.P. Jacquin, L. Uwer, A. Savignoni, J.-M. Ferrero, A. Lortholary, D. Solub, H. Attar-Rabia, S. Deblay, S. Pibre, Y. Belkacemi
Journal: Annals of Oncology (2018)
Abstract 18868: Effects of Immediate Blood Pressure Reduction in Acute Ischemic Stroke by History of Antihypertension Medication Use
Authors: Katherine Obst, Tan Xu, Yonghong Zhang, Hao Peng, Xiaoqing Bu, Chung-Shiuan Chen, Jing Chen, Jiang He
Journal: Circulation (2016)

The optimal strategy for managing elevated blood pressure (BP) in acute ischemic stroke has not been definitively established. In a pre-specified subgroup analysis of CATIS, we examined whether a h...
Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling
Authors: Eric M. Walton, Mark R. Cronan, C.J. Cambier, Andrea Rossi, Michele Marass, Matthew D. Foglia, W. Jared Brewer, Kenneth D. Poss, Didier Y.R. Stainier, Carolyn R. Bertozzi, David M. Tobin
Journal: Cell Host & Microbe (2018)
Up-Regulated Mir-146a Expression in Leukemia Cells Induced By G-CSF Correlates with Enhanced Sensitivity to Cytarabine Treatment: A Putative Novel Predictive Biomarker for Chemotherapy
Authors: Hua Zhong, Xin Li, Jiayi Cai, Yiwei Zhang, Lan Xu, Fei Xiao, Jia Liu, Jiong Hu, Fangyuan Chen
Journal: Blood (2016)
Detection of anti‐type <scp>VII</scp> collagen IgE antibodies in epidermolysis bullosa acquisita
Authors: H. Koga, K. Teye, K. Yamashita, N. Ishii, D. Tsuruta, T. Nakama
Journal: British Journal of Dermatology (2018)

Epidermolysis bullosa acquisita (EBA) is a rare pemphigoid disease involving autoantibodies to type VII collagen (COL7), a major structural component of anchoring fibrils. IgE autoantibodies to type XVII collagen (BP180) have been identified in bullous pemphigoid (BP), the prototype of pemphigoid diseases. Although the pathogenic relevance of IgG anti-COL7 has been investigated, that of IgE in EBA remains unclear.To reveal the presence and pathogenic relevance of IgE anti-COL7 in EBA.We examined IgE antibodies in 109 patients with EBA by indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA).IIF with normal human skin revealed IgE reactivity in the basement membrane zone in 29 (26·6%) cases. To verify whether the IgE antibodies were specific to COL7, we performed IIF with 21 clearly positive cases and the skin of a patient with dystrophic EBA, which does not involve COL7. All cases showed negative results, indicating that IgE antibodies were specific to COL7. In a modified IgG COL7 ELISA for IgE, 16 (14·7%) cases were positive (three and 13 cases were negative and positive on IIF, respectively). We compared anti-COL7 IgG and IgE, and found a weak but significant correlation (r = 0·459, P < 0·001). EBA is clinically divided into a mechanobullous (MB; noninflammatory) type and an inflammatory (INF) type resembling BP. Of the IIF-positive cases, 11 of 30 (37%) had INF and nine of 48 (19%) had MB.This study is the first to demonstrate the presence of circulating anti-COL7 IgE in patients with EBA, which may correlate with the clinical phenotype.
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016
Authors: L. Marandino, A. La Salvia, C. Sonetto, E. De Luca, D. Pignataro, C. Zichi, R.F. Di Stefano, E. Ghisoni, P. Lombardi, A. Mariniello, M.L. Reale, E. Trevisi, G. Leone, L. Muratori, M. Marcato, P. Bironzo, S. Novello, M. Aglietta, G.V. Scagliotti, F. Perrone, M. Di Maio
Journal: Annals of Oncology (2018)

Quality of life (QoL) is a relevant end point and a topic of growing interest by both scientific community and regulatory authorities. Our aim was to review QoL prevalence as an end point in cancer phase III trials published in major journals and to evaluate QoL reporting deficiencies in terms of under-reporting and delay of publication. All issues published between 2012 and 2016 by 11 major journals were hand-searched for primary publications of phase III trials in adult patients with solid tumors. Information about end points was derived from paper and study protocol, when available. Secondary QoL publications were searched in PubMed. In total, 446 publications were eligible. In 210 (47.1%), QoL was not included among end points. QoL was not an end point in 40.1% of trials in the advanced/metastatic setting, 39.7% of profit trials and 53.6% of non-profit trials. Out of 231 primary publications of trials with QoL as secondary or exploratory end point, QoL results were available in 143 (61.9%). QoL results were absent in 37.6% of publications in the advanced/metastatic setting, in 37.1% of profit trials and 39.3% of non-profit trials. Proportion of trials not including QoL as end point or with missing QoL results was relevant in all tumor types and for all treatment types. Overall, 70 secondary QoL publications were found: for trials without QoL results in the primary publication, probability of secondary publication was 12.5%, 30.9% and 40.3% at 1, 2 and 3 years, respectively. Proportion of trials not reporting QoL results was similar in trials with positive results (36.5%) and with negative results (39.4%), but the probability of secondary publication was higher in positive trials. QoL is not included among end points in a relevant proportion of recently published phase III trials in solid tumors. In addition, QoL results are subject to significant under-reporting and delay in publication.
Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma: A preliminary analysis of a multicenter, prospective phase II study (BRiZ2012)
Authors: M. Kanno, K. Miura, Y. Masaki, H. Tsujimura, M. Iino, J. Takizawa, Y. Maeda, K. Yamamoto, S. Tamura, A. Yoshida, H. Yagi, I. Yoshida, K. Kitazume, T. Masunari, I. Choi, Y. Kakinoki, T. Yoshino, S. Nakamura, T. Yoshida
Journal: Annals of Oncology (2018)
GW29-e0869 Features Of Cytokine Status In Patients With Coronary Heart Disease
Authors: Anis Alyavi, Baxrom Alyavi, Dildora Karimova, Diyora Radjabova, Jamol Uzokov, Jasur Toshev, Bekzod Shodiev
Journal: Journal of the American College of Cardiology (2018)
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
Authors: Patricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodriguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot
Journal: Blood (2018)
GW29-e0033 Combination of Atorvastatin and Atorvastatin-pretreated Mesenchymal Stem Cells Improves the Cardiac Performance after Acute Myocardial Infarction by Targeting SDF-1/CXCR4 axis
Authors: Xiaqiu Tian, Yuejin Yang
Journal: Journal of the American College of Cardiology (2018)
Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy
Authors: N. Duma, A.-G. Azzouqa, S. Yadav, K. Hoversten, C. Reed, A.N. Sitek, Y. Lou, J. Molina, T. Halfdanarson, K. Leventakos, R.W. Joseph, R. Manochakian, R. Dronca
Journal: Annals of Oncology (2018)